Lilly scores against Novo Nordisk in weight loss contest

There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be better at achieving weight loss.